OZ Biosciences Patent & NANOMED New Partnership
The US patent number 9,107,931 has been issued to OZ Biosciences for its new class of cationic lipids for transporting active agents into cells. OZ Biosciences is glad to be an associated partner of NANOMED project H2020-MSCA-ITN-2015.
CASE 922 - MARSEILLE CEDEX 09, France, September 22, 2015 (Newswire.com) - Awarded patent on Cationic lipids for transporting active agents into cells
Marseille September 22 2015 - OZ BIOSCIENCES, a french biotech company specialized in the development of innovative transfection and transduction reagents, has been granted patent number 9,107,931 by the U.S. Patent and Trademark Office for its class of cationic lipids for transporting active agents into cells, which reinforces its position as expert in molecular delivery systems.
"OZ Biosciences's goal has always been to provide cutting-edge transfection and transduction reagents to enable life sciences researchers to achieve outstanding results” said Olivier Zelphati, CEO of OZ Biosciences. “Our R&D team has more than 10 years of experience in developing transfection reagents, transduction enhancers and we are gratified that our innovative work has been recognized with the allowance of a US patent.”
With more than 65 products in its portfolio, OZ BIOSCIENCES offer a complete transfection reagents portfolio that includes MagnetofectionTM (magnet-assisted transfection) reagents as well as lipid-based and polymer-based transfection reagents. Our R&D work is focused on developing transfection reagents for any types of cells (immortalized, Hard-to-transfect and primary cells) and for in vivo applications.
In addition, the project “Nanomedicine: an integrative approach” (NANOMED) submitted to the MARIE SKŁODOWSKA-CURIE ACTIONS HEALTH, H2020-MSCA-ITN-2015, in which OZ BIOSCIENCES is an associated partner, has been awarded by the European Commission. The aims of the call are to support translational research proposals that combine innovative approaches in the field of Nanomedicine and to encourage and enable translational collaboration between public and private research groups. The funding boosts scientific excellence and business innovation, and enhances researchers’ career prospects through developing their skills in entrepreneurship, creativity and innovation.
About OZ BIOSCIENCES:
Since 2003, OZ Biosciences creates, develops and produces innovative molecular delivery systems specialized in transfection and transduction tools, for the worldwide scientific community and pharmaceutical industry. OZ Biosciences is focused on delivery technologies of biomolecules such as DNA, RNA and protein for in vitro and in vivo applications. The company has established a strong position in the field of molecular delivery system with several patents and know-how for Magnetofection™, Magneto-biolisitic, Magnetic-assisted transduction, Polyfection, Lipofection and 3D transfection, technologies.
OZ Biosciences has developed comprehensive product lines:
1. Magnetofection™: a unique gene delivery method for in vitro and in vivo applications.
2. Lipofection: proprietary biodegradable lipid-based transfection reagents.
3. Transduction tools: for producing, concentrating, storing and enhancing virus efficiency.
4. 3D transfection: allowing nucleic acid delivery directly into 3D matrix.
5. Protein delivery systems: including antibody & based on biodegradable lipid nanoparticles.
6. Cell specific reagents: For specific cells such as neurons and stem cells.
7. Vaccine Adjuvants: Standard & novel adjuvants for antigenic & genetic immunization
8. Nucleic acids: a selection of stabilized mRNAs, DNA and siRNA (Reporters, Genome Editing, Transcription factors…)
For more information, please visit: www.ozbiosciences.com